Skip to content
DataLookout
Start free
Menu

ITINERANCENCT07634718

Implementation Trial In patieNts With rEnal failuRe and diAbetes for Major Adverse reNal and Cardiovascular Events

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Primary completion date: Jun 2029 to Jul 15, 2029
    • Study completion date: Jun 2032 to Jun 15, 2032
    • Start date changed from estimate of Jun 2026 to Jul 15, 2026
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Major Adverse Renal and Cardiovascular Events (MARCE) occurrence
Timeframe: 2 years after randomization and dissemination of health-related messages

Secondary (4)

Specific health outcomes
Reimbursement claims of medications of special interest and visits to general practitioners and to specialists in cardiology, nephrology and diabetology
Biological characteristics
Impact on medical costs

Arms and interventions

health-related armExperimental

Participants will receive an health-related message included in the biological results form. A short graphical illustration will indicate the patient-risk level according the biological results and video detailing national recommendations. HCPs will receive a SIGNAL BIO message which was elaborated on evidence-based treatments and/or strategy for patients with diabetes.

Control groupNo intervention

Participants will get as in the routine care, no message will be disseminated for this group.

Other: Health-related messages

Sites

1 site in 1 country

  • Biogroup laboratoriesNantes, France